Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Pharmaceutical development of novel lactate-based 6-fluoro-l-DOPA formulations.

Denora N, Lopedota A, de Candia M, Cellamare S, Degennaro L, Luisi R, Mele A, Tricarico D, Cutrignelli A, Laquintana V, Altomare CD, Franco M, Dimiccoli V, Tolomeo A, Scilimati A.

Eur J Pharm Sci. 2017 Mar 1;99:361-368. doi: 10.1016/j.ejps.2016.10.001. Epub 2016 Oct 4.

PMID:
27717874
2.

Association of the mt-ND2 5178A/C polymorphism with Parkinson's disease.

Gusdon AM, Fang F, Chen J, Mathews CE, Li W, Chu CT, Ding JQ, Chen SD.

Neurosci Lett. 2015 Feb 5;587:98-101. doi: 10.1016/j.neulet.2014.12.005. Epub 2014 Dec 12.

3.

PGC-1β mediates adaptive chemoresistance associated with mitochondrial DNA mutations.

Yao Z, Jones AW, Fassone E, Sweeney MG, Lebiedzinska M, Suski JM, Wieckowski MR, Tajeddine N, Hargreaves IP, Yasukawa T, Tufo G, Brenner C, Kroemer G, Rahman S, Szabadkai G.

Oncogene. 2013 May 16;32(20):2592-600. doi: 10.1038/onc.2012.259. Epub 2012 Jul 9.

PMID:
22777349
4.

Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease.

Blackinton J, Kumaran R, van der Brug MP, Ahmad R, Olson L, Galter D, Lees A, Bandopadhyay R, Cookson MR.

Neurosci Lett. 2009 Mar 6;452(1):8-11. doi: 10.1016/j.neulet.2008.12.053. Epub 2009 Jan 6.

5.

Complex I polymorphisms, bigenomic heterogeneity, and family history in Virginians with Parkinson's disease.

Swerdlow RH, Weaver B, Grawey A, Wenger C, Freed E, Worrall BB.

J Neurol Sci. 2006 Sep 25;247(2):224-30. Epub 2006 Jun 19.

6.

Parkinson disease: analysis of mitochondrial DNA in monozygotic twins.

Kösel S, Grasbon-Frodl EM, Hagenah JM, Graeber MB, Vieregge P.

Neurogenetics. 2000 Mar;2(4):227-30.

PMID:
10983718
7.

Variability and validity of polymorphism association studies in Parkinson's disease.

Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T.

Neurology. 2000 Aug 22;55(4):533-8.

PMID:
10953187
8.

Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease.

Kösel S, Grasbon-Frodl EM, Mautsch U, Egensperger R, von Eitzen U, Frishman D, Hofmann S, Gerbitz KD, Mehraein P, Graeber MB.

Neurogenetics. 1998 Mar;1(3):197-204.

PMID:
10737123
9.

Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist.

Bédard MA, el Massioui F, Malapani C, Dubois B, Pillon B, Renault B, Agid Y.

Clin Neuropharmacol. 1998 Mar-Apr;21(2):108-17.

PMID:
9579297
10.

The 'common deletion' is not increased in parkinsonian substantia nigra as shown by competitive polymerase chain reaction.

Kösel S, Egensperger R, Schnopp NM, Graeber MB.

Mov Disord. 1997 Sep;12(5):639-45.

PMID:
9380043
11.

Regional heterogeneity of mtDNA heteroplasmy in parkinsonian brain.

Schnopp NM, Kösel S, Egensperger R, Graeber MB.

Clin Neuropathol. 1996 Nov-Dec;15(6):348-52.

PMID:
8937782
12.

Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism.

Kösel S, Lücking CB, Egensperger R, Mehraein P, Graeber MB.

J Neurosci Res. 1996 Apr 15;44(2):174-83.

PMID:
8723226

Supplemental Content

Loading ...
Support Center